Cancers, Free Full-Text

After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontology of disease have led to targeting mutations in isocitrate dehydrogenase, FMS-like tyrosine kinase 3 (FLT3), B-cell lymphoma 2 and hedgehog pathways. Yet outcomes remain variable; especially in defined molecular and genetic subgroups such as NPM1 (Nucleophosmin 1) mutations, 11q23/KMT2A rearranged and TP53 mutations. Emerging therapies seek to address these unmet needs, and all three of these subgroups have promising new therapeutic approaches. Here, we will discuss the normal biological roles of menin in acute leukemia, notably in KMT2A translocations and NPM1 mutation, as well as current drug development. We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

PDF) Treatment outcome with low-dose-rate interstitial brachytherapy in early-stage oral tongue cancers

Cancers, Free Full-Text

Spatial genomics maps the structure, nature and evolution of cancer clones

Cancers, Free Full-Text

Epigenetic regulation during cancer transitions across 11 tumour types

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial - The Lancet

Cancers, Free Full-Text

Cancer-Free with Food: A Step-by-Step by Werner Gray, Liana

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer